Mirikizumab

Mirikizumab is an experimental monoclonal antibody designed for the treatment of psoriasis, ulcerative colitis, and Crohn's disease. It is developed by Eli Lilly and Company.

Mechanism of action

Mirikizumab works by targeting interleukin 23, a molecule that plays a key role in inflammatory processes of the immune system and is thought to be linked to a number of chronic immune diseases, including psoriasis and ulcerative colitis.

Clinical trials

Phase 2 trials for psoriasis showed promising results for mirikizumab. Most patients in the trial achieved significant skin clearance, with a clear or almost clear skin rating of 0/1 on the Psoriasis Area and Severity Index (PASI), and a 90% reduction in the PASI score (PASI 90).

Mirikizumab has also undergone Phase 2 trials for ulcerative colitis. Results indicated that the drug was well tolerated and met the primary endpoint of the study.

Development

The development of mirikizumab is being carried out by Eli Lilly and Company. The drug is currently in Phase 3 clinical trials.

See also

• List of investigational drugs
• Monoclonal antibodies (mAbs)
• Interleukin 23
• Psoriasis
• Ulcerative colitis
• Crohn's disease